Autres avocats qui pourraient vous intéresser
Emma Danks is head of our UK corporate/M&A group, co-head of our global corporate/M&A group and a member of the UK Executive Board. She is recognised as one of the UK’s leading private equity lawyers and is described by clients as bright, commercial, and solutions focused. Emma is well known for her work with private equity sponsors and their portfolio companies, having acted on a wide range of leveraged buyouts and related transactions. She also frequently advises private equity backed management teams on buyout transactions and equity plans.
Emma also has specific life sciences and healthcare experience, having acted for several generic pharmaceutical companies on both buy-side and sell-side M&A transactions, as well as PE sponsors investing in this sector.
Emma was listed in The Lawyer's Hot 100 for 2018, and in the Legal Business feature on the City's female deal stars. Her team’s buyout expertise was recently recognised when they were named Private Equity Team of the Year at the British Legal Awards.
Since 2023 | Member of the UK Executive Board, Taylor Wessing |
Since 2019 | Head of UK Corporate Group and Co-head of the International Corporate group, Taylor Wessing |
2017 - 2023 | Head of the Private Equity group, Taylor Wessing |
Since 2010 | Partner, Taylor Wessing |
2006 - 2010 | Senior Associate, Clifford Chance |
2001 - 2006 | Associate, Clifford Chance |
1999 - 2001 | Trainee, Clifford Chance |
2001 | Admitted as a lawyer, England & Wales |
1998 | CPE and LPC, College of Law, Guildford |
1996 | MA Hons Newnham College, University of Cambridge |
Private Equity Exits “A Practical Analysis", October 2011 and re-issued in 2021 |
Actualités et publications récentes
Advising Leica Geosystems on its acquisition of Xwatch Safety Solutions Limited
par plusieurs auteurs
M&A Summit 2024: discussing the latest trends in global M&A
par Emma Danks et Suzy Davis
Advising Carlyle-supported SER group on new investment from TA Associates
par plusieurs auteurs
Advising Bridgepoint on its investment in Identicare
par Emma Danks et Jonny Bethell